GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer
Shots:
- The US FDA has approved Jemperli (dostarlimab) + CT (carboplatin & paclitaxel) followed by Jemperli alone to treat adults with primary advanced or recurrent endometrial cancer, supported by part 1 of P-III (RUBY) study
- The P-III (RUBY) study was carried out in 2 parts, with part 1 assessing Jemperli + CT followed by Jemperli vs CT + PBO followed by PBO & part 2 assessing Jemperli + CT followed by Jemperli + niraparib vs PBO + CT followed by PBO to treat endometrial cancer
- Part 1 results showed OS benefit in the full population with a reduction in death risk of 31%. After 2.5yrs. 61% vs 49% of them were alive; a 16.4mos. improvement in mOS (44.6mos. vs 28.2mos.) was observed at a median follow-up of >3yrs.
Ref: GSK | Image: GSK
Related News:- GSK Highlights the P-III (RUBY) Trial Results of Jemperli to Treat Endometrial Cancer at Society of Gynecologic Oncology 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
